• Anavex received a Nasdaq delinquency notice on May 20, 2026, citing noncompliance with Listing Rule 5250(c)(1) tied to its failure to file its Form 10-Q for the quarter ended March 31, 2026, on time.
• The company has until July 20, 2026, to submit a compliance plan while it works to complete the filing.
• The notice has no immediate effect on trading of the stock on Nasdaq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000781), on May 22, 2026, and is solely responsible for the information contained therein.